Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Ocean Power Technologies Announces Delivery of WAM-V® Maritime Drone to Stevens Institute of Technology

Ocean Power Technologies Announces Delivery of WAM-V® Maritime Drone to Stevens Institute of Technology

Ocean Power Technologies (NYSE American: OPTT) has successfully delivered its WAM-V® unmanned surface vehicle to Stevens Institute of Technology, marking completion of the customer order announced in June 2026. The delivery was completed in five weeks, highlighting OPT's enhanced manufacturing and operational capabilities. This milestone underlines…

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on cancer drug development, will report its second quarter 2026 financial results and provide a corporate update on August 13, 2026. The company is developing several targeted cancer therapies using its proprietary Phospholipid Drug Conjugate platform, with multiple FDA …

PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026

PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026

PetMed Express, a leading online pet pharmacy, will release its financial results for the first quarter ended June 30, 2026, on August 13, 2026. The company will hold a conference call and webcast to discuss the results. PetMed Express operates nationally and offers a wide range of pet healthcare products through its PetMeds and PetCareRx brands.

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics, a leader in CRISPR gene editing therapies, announced it will hold a conference call on August 6, 2026, to discuss its second quarter financial results and provide updates on its business. The company continues to focus on developing potentially curative treatments for severe diseases leveraging gene editing technologies.

Euronet Worldwide Reports Second Quarter 2026 Financial Results

Euronet Worldwide Reports Second Quarter 2026 Financial Results

Euronet Worldwide announced its second quarter 2026 financial results, highlighting a 3% revenue increase to $1.108 billion and a 10% increase in adjusted earnings per share to $2.82. The company demonstrated strong growth in its digital accelerator revenue, which increased 31% year over year and represented 26% of total revenues. Strategic initiat…

Immutep Quarterly Activities Report Q4 FY26

Immutep Quarterly Activities Report Q4 FY26

Immutep Limited provided its Q4 FY26 activities update, highlighting positive pooled analysis results from efti trials demonstrating a 7.7-month median overall survival benefit in responders across multiple cancers. However, the Phase III TACTI-004 trial in first-line NSCLC was discontinued due to futility. Encouraging Phase I results were presente…

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Iovance Biotherapeutics, a biotechnology firm specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer, will report its Q2 2026 financial results and corporate updates on August 6, 2026. The company is a leader in TIL therapy innovation, with its Amtagvi® therapy approved by the FDA for solid tumors. The webcast aims to provide inve…

ASP Isotopes to Participate in Canaccord Genuity’s 46th Annual Growth Conference on August 12, 2026

ASP Isotopes to Participate in Canaccord Genuity’s 46th Annual Growth Conference on August 12, 2026

ASP Isotopes Inc. announced that its Chief Commercial Officer will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company focuses on advanced isotope enrichment technologies for critical materials in sectors such as nuclear medicine, semiconductors, and nuclear energy. Additionally, ASP Isotopes is involved i…

ZenaTech's DaaS Oil and Gas Business Enters a Strengthened Market with Higher Oil Prices and More Than US$500 Billion in Expected Canadian Energy Investment Over the Next Decade

ZenaTech's DaaS Oil and Gas Business Enters a Strengthened Market with Higher Oil Prices and More Than US$500 Billion in Expected Canadian Energy Investment Over the Next Decade

ZenaTech, Inc. announced the acquisition of Velocity Geomatics, a drone-based surveying and regulatory compliance service provider for the oil and gas sector in Western Canada. This move expands ZenaTech's Drone as a Service (DaaS) business amid a favorable market, supported by a 45% year-over-year increase in crude oil prices and over $500 billion…

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Aprea Therapeutics updates clinical progress on APR-1051, its oral WEE1 inhibitor, reporting accelerated enrollment and plans to expand development into combination regimens for multiple biomarker-defined cancers. The company anticipates presenting new Phase 1 data from ACESOT-1051 in Q4 2026, supporting further dose escalation and development in u…

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Verrica Pharmaceuticals will report its second quarter 2026 financial results on August 6, 2026, and provide a corporate update via conference call and webcast. The company focuses on dermatological disease treatments, including FDA-approved YCANTH® for molluscum contagiosum and pipeline products targeting common warts and non-melanoma skin cancers…

Uniti Group Inc. Reports Second Quarter 2026 Results

Uniti Group Inc. Reports Second Quarter 2026 Results

Uniti Group Inc. announced its second quarter 2026 financial results, highlighting record new bookings at its Fiber Infrastructure segment and strong growth in Kinetic Consumer Fiber revenue and subscriber base. The company updated its full-year 2026 outlook with consolidated revenue expected between $3.63 billion and $3.68 billion, and adjusted EB…

Stride Announces CEO Succession

Stride Announces CEO Succession

Stride, Inc. announced the appointment of Robert Knowling as CEO succeeding James Rhyu, and named Steven Fink as Chair of the Board. Brian Shepherd joins the board to strengthen leadership amid a focus on growth and innovation. The company reported strong preliminary fiscal year 2026 financial results with increases in revenue, operating income, an…